Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) has provided an announcement.
Japan Tissue Engineering announced that its autologous cultured cartilage product JACC will be newly covered by Japan’s national health insurance for an expanded indication that now includes knee osteoarthritis, effective January 1, 2026. JACC, already approved and reimbursed for traumatic cartilage defects and osteochondritis dissecans, becomes available as an insured regenerative treatment for patients whose knee osteoarthritis symptoms do not improve with conservative therapies and who have a defined minimum cartilage defect area, with reimbursement set at 1 million yen for the tissue transport set and 1.89 million yen for the cultured cartilage package. The broader insurance coverage is expected to increase patient access to advanced cartilage repair, strengthen J-TEC’s position in orthopedic regenerative medicine, and support the company’s strategy to expand its business while enhancing clinical outcomes and quality of life for an aging population with rising knee joint disorders.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. (J-TEC) is a Japanese regenerative medicine company specializing in tissue-engineered products that use patients’ own cells, with a growing focus on orthopedic applications such as cartilage repair. The company develops and commercializes advanced cell-based therapies aimed at improving patients’ quality of life and expanding treatment options in fields where conventional therapies are limited.
Average Trading Volume: 62,167
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen20.1B
Learn more about 7774 stock on TipRanks’ Stock Analysis page.